Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Cell Signaling in Cancer and Cancer Therapy
share announcement

Cell Signaling in Cancer and Cancer Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 6156

Special Issue Editors

Prof. Dr. Zhixiang Wang

E-Mail Website
Guest Editor
Signal Transduction Research Group, Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada
Interests: receptor tyrosine kinases; EGFR; signal transduction; cancer therapy; breast cancer treatment; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Dr. Yi Wang

E-Mail Website
Guest Editor
1. Canadian Nuclear Laboratories, Chalk River, ON, Canada
2. Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
Interests: cancer therapy; radiation therapy; targeted therapy; immune checkpoint therapy; low dose radiation; hypoxia; microenvironment; cell signalling

Special Issue Information

Dear Colleagues,

Cancer is driven by genetic and epigenetic modifications to enable cells to over-proliferate and escape from cell death. One hallmark of cancer is the aberrant cell signaling which is caused by the dysregulation of signaling proteins. Cell signaling plays a prominent role in regulating cell growth and division, cell death, cell fate, and cell motility. In a wider context, the microenvironment, angiogenesis, and inflammation are also governed by external and internal signals. These signals are transmitted in a highly intricate and tightly controlled manner through a series of signaling proteins. Hyperactivation or dysregulation of these signaling pathways, for example, PI3K-Akt and Ras-ERK pathways, can result in transformation of cellular proto-oncogenes to oncogenes. On the other hand, the inactivation of tumor suppressors eliminates important negative regulators of signaling, which results in uncontrolled cell proliferation and subsequent tumor development. The knowledge of cellular signal transduction pathways will be essential to understand the evolution of a pathological condition and the delicate balance that regulates cellular homeostasis.

Recently, targeting the component of cell signaling (either at cells such as targeted therapy or at microenvironment such as immune therapy) in cancer has emerged as the most prominent aspect of cancer treatment. In order to specially design novel drugs that intervene at dysregulated signaling nodes or repair missing signaling molecules, it is crucial to understand how oncogenic signaling pathways control the development of cancer.

In this Special Issue, we invite all papers that study the cell signaling underlying any aspects of cancer development. Research on the signaling pathway behind cancer therapies including targeted, immune, radiation and chemo-therapy are also welcomed. This Special Issue invites both original research articles as well as reviews, commentaries, and perspectives that cover all aspects of signal transduction.

Prof. Dr. Zhixiang Wang
Dr. Yi Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cell signaling
  • signal transduction
  • cancer therapy
  • radiation therapy
  • immune therapy
  • targeted therapy
  • chemotherapy
  • cell proliferation
  • cell death
  • cell motility

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

24 pages, 10914 KiB  
Article
The Tumor Suppressor SOCS1 Diminishes Tolerance to Oxidative Stress in Hepatocellular Carcinoma
by Akhil Shukla, Md Gulam Musawwir Khan, Anny Armas Cayarga, Mozhdeh Namvarpour, Mohammad Mobarak H. Chowdhury, Dominique Levesque, Jean-François Lucier, François-Michel Boisvert, Sheela Ramanathan and Subburaj Ilangumaran
Cancers 2024, 16(2), 292; https://doi.org/10.3390/cancers16020292 - 10 Jan 2024
Cited by 1 | Viewed by 862
Abstract
SOCS1 is a tumor suppressor in hepatocellular carcinoma (HCC). Recently, we showed that a loss of SOCS1 in hepatocytes promotes NRF2 activation. Here, we investigated how SOCS1 expression in HCC cells affected oxidative stress response and modulated the cellular proteome. Murine Hepa1-6 cells [...] Read more.
SOCS1 is a tumor suppressor in hepatocellular carcinoma (HCC). Recently, we showed that a loss of SOCS1 in hepatocytes promotes NRF2 activation. Here, we investigated how SOCS1 expression in HCC cells affected oxidative stress response and modulated the cellular proteome. Murine Hepa1-6 cells expressing SOCS1 (Hepa-SOCS1) or control vector (Hepa-Vector) were treated with cisplatin or tert-butyl hydroperoxide (t-BHP). The induction of NRF2 and its target genes, oxidative stress, lipid peroxidation, cell survival and cellular proteome profiles were evaluated. NRF2 induction was significantly reduced in Hepa-SOCS1 cells. The gene and protein expression of NRF2 targets were differentially induced in Hepa-Vector cells but markedly suppressed in Hepa-SOCS1 cells. Hepa-SOCS1 cells displayed an increased induction of reactive oxygen species but reduced lipid peroxidation. Nonetheless, Hepa-SOCS1 cells treated with cisplatin or t-BHP showed reduced survival. GCLC, poorly induced in Hepa-SOCS1 cells, showed a strong positive correlation with NFE2L2 and an inverse correlation with SOCS1 in the TCGA-LIHC transcriptomic data. A proteomic analysis of Hepa-Vector and Hepa-SOCS1 cells revealed that SOCS1 differentially modulated many proteins involved in diverse molecular pathways, including mitochondrial ROS generation and ROS detoxification, through peroxiredoxin and thioredoxin systems. Our findings indicate that maintaining sensitivity to oxidative stress is an important tumor suppression mechanism of SOCS1 in HCC. Full article
(This article belongs to the Special Issue Cell Signaling in Cancer and Cancer Therapy)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

16 pages, 2489 KiB  
Review
Extracellular Signal-Regulated Kinases: One Pathway, Multiple Fates
by Xavier Deschênes-Simard, Mohan Malleshaiah and Gerardo Ferbeyre
Cancers 2024, 16(1), 95; https://doi.org/10.3390/cancers16010095 - 24 Dec 2023
Viewed by 1135
Abstract
This comprehensive review delves into the multifaceted aspects of ERK signaling and the intricate mechanisms underlying distinct cellular fates. ERK1 and ERK2 (ERK) govern proliferation, transformation, epithelial–mesenchymal transition, differentiation, senescence, or cell death, contingent upon activation strength, duration, and context. The biochemical mechanisms [...] Read more.
This comprehensive review delves into the multifaceted aspects of ERK signaling and the intricate mechanisms underlying distinct cellular fates. ERK1 and ERK2 (ERK) govern proliferation, transformation, epithelial–mesenchymal transition, differentiation, senescence, or cell death, contingent upon activation strength, duration, and context. The biochemical mechanisms underlying these outcomes are inadequately understood, shaped by signaling feedback and the spatial localization of ERK activation. Generally, ERK activation aligns with the Goldilocks principle in cell fate determination. Inadequate or excessive ERK activity hinders cell proliferation, while balanced activation promotes both cell proliferation and survival. Unraveling the intricacies of how the degree of ERK activation dictates cell fate requires deciphering mechanisms encompassing protein stability, transcription factors downstream of ERK, and the chromatin landscape. Full article
(This article belongs to the Special Issue Cell Signaling in Cancer and Cancer Therapy)
►▼ Show Figures

Graphical abstract

19 pages, 7011 KiB  
Review
Semaphorin 6 Family—An Important Yet Overlooked Group of Signaling Proteins Involved in Cancerogenesis
by Wiktor Wagner, Błażej Ochman and Waldemar Wagner
Cancers 2023, 15(23), 5536; https://doi.org/10.3390/cancers15235536 - 22 Nov 2023
Viewed by 1246
Abstract
According to recent evidence, some groups of semaphorins (SEMAs) have been associated with cancer progression. These proteins are able to modulate the cellular signaling of particular receptor tyrosine kinases (RTKs) via the stimulation of SEMA-specific coreceptors, namely plexins (plexin-A, -B, -C, -D) and [...] Read more.
According to recent evidence, some groups of semaphorins (SEMAs) have been associated with cancer progression. These proteins are able to modulate the cellular signaling of particular receptor tyrosine kinases (RTKs) via the stimulation of SEMA-specific coreceptors, namely plexins (plexin-A, -B, -C, -D) and neuropilins (Np1, Np2), which share common domains with RTKs, leading to the coactivation of the latter receptors. MET, ERBB2, VEGFR2, PFGFR, and EGFR, among others, represent acknowledged targets of semaphorins that are often associated with tumor progression or poor prognosis. In particular, higher expression of SEMA6 family proteins in cancer cells and stromal cells of the cancer niche is often associated with enhanced tumor angiogenesis, metastasis, and resistance to anticancer therapy. Notably, high SEMA6 expression in malignant tumor cells such as melanoma, pleural mesothelioma, gastric cancer, lung adenocarcinoma, and glioblastoma may serve as a prognostic biomarker of tumor progression. To date, very few studies have focused on the mechanisms of transmembrane SEMA6-driven tumor progression and its underlying interplay with RTKs within the tumor microenvironment. This review presents the growing evidence in the literature on the complex and shaping role of SEMA6 family proteins in cancer responsiveness to environmental stimuli. Full article
(This article belongs to the Special Issue Cell Signaling in Cancer and Cancer Therapy)
►▼ Show Figures

Figure 1

23 pages, 1046 KiB  
Review
Targeted Alpha Therapy (TAT) with Single-Domain Antibodies (Nanobodies)
by Kate Hurley, Meiyun Cao, Haiming Huang and Yi Wang
Cancers 2023, 15(13), 3493; https://doi.org/10.3390/cancers15133493 - 04 Jul 2023
Viewed by 2032
Abstract
The persistent threat of cancer necessitates the development of improved and more efficient therapeutic strategies that limit damage to healthy tissues. Targeted alpha therapy (TαT), a novel form of radioimmuno-therapy (RIT), utilizes a targeting vehicle, commonly antibodies, to deliver high-energy, but short-range, alpha-emitting [...] Read more.
The persistent threat of cancer necessitates the development of improved and more efficient therapeutic strategies that limit damage to healthy tissues. Targeted alpha therapy (TαT), a novel form of radioimmuno-therapy (RIT), utilizes a targeting vehicle, commonly antibodies, to deliver high-energy, but short-range, alpha-emitting particles specifically to cancer cells, thereby reducing toxicity to surrounding normal tissues. Although full-length antibodies are often employed as targeting vehicles for TαT, their high molecular weight and the presence of an Fc-region lead to a long blood half-life, increased bone marrow toxicity, and accumulation in other tissues such as the kidney, liver, and spleen. The discovery of single-domain antibodies (sdAbs), or nanobodies, naturally occurring in camelids and sharks, has introduced a novel antigen-specific vehicle for molecular imaging and TαT. Given that nanobodies are the smallest naturally occurring antigen-binding fragments, they exhibit shorter relative blood half-lives, enhanced tumor uptake, and equivalent or superior binding affinity and specificity. Nanobody technology could provide a viable solution for the off-target toxicity observed with full-length antibody-based TαT. Notably, the pharmacokinetic properties of nanobodies align better with the decay characteristics of many short-lived α-emitting radionuclides. This review aims to encapsulate recent advancements in the use of nanobodies as a vehicle for TαT. Full article
(This article belongs to the Special Issue Cell Signaling in Cancer and Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop